{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:51:48Z","timestamp":1788306708886,"version":"build-2803163510"},"reference-count":25,"publisher":"BMJ","issue":"2","funder":[{"name":"GAIN Charity"},{"DOI":"10.13039\/100013560","name":"GBS-CIDP Foundation International","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013560","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Annexon"},{"DOI":"10.13039\/501100000853","name":"Glasgow University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Erasmus University Medical Centre"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2019,9,18]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare disease course in patients with Guillain-Barr\u00e9 syndrome (GBS) with a poor prognosis who were treated with one or with two intravenous immunoglobulin (IVIg) courses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From the International GBS Outcome Study, we selected patients whose modified Erasmus GBS Outcome Score at week 1 predicted a poor prognosis. We compared those treated with one IVIg course to those treated with two IVIg courses. The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivariable ordinal regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 237 eligible patients, 199 patients received a single IVIg course. Twenty patients received an \u2018early\u2019 second IVIg course (1\u20132 weeks after start of the first IVIg course) and 18 patients a \u2018late\u2019 second IVIg course (2\u20134 weeks after start of IVIg). At baseline and 1\u2009week, those receiving two IVIg courses were more disabled than those receiving one course. Compared with the one course group, the adjusted OR for a better GBS disability score at 4 weeks was 0.70 (95%CI 0.16 to 3.04) for the early group and 0.66 (95%CI 0.18 to 2.50) for the late group. The secondary endpoints were not in favour of a second IVIg course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This observational study did not show better outcomes after a second IVIg course in GBS with poor prognosis. The study was limited by small numbers and baseline imbalances. Lack of improvement was likely an incentive to start a second IVIg course. A prospective randomised trial is needed to evaluate whether a second IVIg course improves outcome in GBS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2019-321496","type":"journal-article","created":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T17:19:15Z","timestamp":1570295955000},"page":"113-121","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Original research: Second IVIg course in Guillain-Barr\u00e9 syndrome with poor prognosis: the non-randomised ISID study"],"prefix":"10.1136","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-6679","authenticated-orcid":false,"given":"Christine","family":"Verboon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Cornblath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmee","family":"Venema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C","family":"Gorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Lingsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Pereon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren H","family":"Sindrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1584-8704","authenticated-orcid":false,"given":"Susumu","family":"Kusunoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhahirul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govindsinh","family":"Chavada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart C","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A C","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,5]]},"reference":[{"key":"2024111108000871000_91.2.113.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"2024111108000871000_91.2.113.2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm004"},{"key":"2024111108000871000_91.2.113.3","doi-asserted-by":"crossref","unstructured":"Hughes RAC , Swan AV , van Doorn PA , et al . Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev 2014;46. CD002063.doi:10.1002\/14651858.CD002063.pub6","DOI":"10.1002\/14651858.CD002063.pub6"},{"key":"2024111108000871000_91.2.113.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705"},{"key":"2024111108000871000_91.2.113.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121"},{"key":"2024111108000871000_91.2.113.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314862"},{"key":"2024111108000871000_91.2.113.7","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(97)24050-X","article-title":"Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barr\u00e9 syndrome","volume":"350","author":"Farcas","year":"1997","journal-title":"Lancet"},{"key":"2024111108000871000_91.2.113.8","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21737"},{"key":"2024111108000871000_91.2.113.9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.24358","article-title":"Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs","volume":"91","author":"Ammann","year":"2016","journal-title":"Am J Hematol"},{"key":"2024111108000871000_91.2.113.10","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000050","article-title":"Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg: table","volume":"1","author":"Nguyen","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024111108000871000_91.2.113.11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"key":"2024111108000871000_91.2.113.12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jns.12209","article-title":"International Guillain-Barr\u00e9 syndrome outcome study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barr\u00e9 syndrome","volume":"22","author":"Jacobs","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"2024111108000871000_91.2.113.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e07d14"},{"key":"2024111108000871000_91.2.113.14","unstructured":"SID-GBS trial. Available: http:\/\/www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=2224"},{"key":"2024111108000871000_91.2.113.15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jns.12286","article-title":"Second IVIg course in Guillain-Barr\u00e9 syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial","volume":"23","author":"Walgaard","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"2024111108000871000_91.2.113.16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"2024111108000871000_91.2.113.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.01.014"},{"key":"2024111108000871000_91.2.113.18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial of prednisolone in acute polyneuropathy","volume":"312","author":"Hughes","year":"1978","journal-title":"The Lancet"},{"key":"2024111108000871000_91.2.113.19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285"},{"key":"2024111108000871000_91.2.113.20","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880141111"},{"key":"2024111108000871000_91.2.113.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440512"},{"key":"2024111108000871000_91.2.113.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.03.011"},{"key":"2024111108000871000_91.2.113.23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamaneurol.2016.4480","article-title":"Association of albumin levels with outcome in intravenous Immunoglobulin-Treated Guillain-Barr\u00e9 syndrome","volume":"74","author":"Fokkink","year":"2017","journal-title":"JAMA Neurol"},{"key":"2024111108000871000_91.2.113.24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/jns.12234","article-title":"Markers for Guillain-Barr\u00e9 syndrome with poor prognosis: a multi-center study","volume":"22","author":"Yamagishi","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"2024111108000871000_91.2.113.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3603"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2019-321496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T11:02:07Z","timestamp":1731322927000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2019-321496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,5]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1,10]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/jnnp-2019-321496"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2019-321496","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,5]]}}}